Practice question

Pseudomurein represents fascinating case of convergent evolution where archaeal methanogens assemble wall polymer with superficial resemblance to bacterial peptidoglycan but distinct sugar composition rendering it insensitive to many antibacterial agents. In bacterial murein, alternating N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) linked beta-1,4 carry lactyl ether with short peptide containing D-amino acids. Archaeal pseudomurein replaces NAM with N-acetyl-D-talosaminuronic acid, abbreviated NAT, which is N-acetylglucosamine epimer bearing carboxyl group at different position and lacking D-lactyl substituent. NAT is generated through separate biosynthetic pathway, providing similar backbone function but altered stereochemistry. Lipoarabinomannan is mycobacterial glycolipid, not part of pseudomurein. This substitution, combined with use of L-glutamate, L-alanine, and L-lysine in interpeptide bridges, makes wall resistant to lysozyme that specifically recognizes NAM, and to penicillin which targets D-Ala-D-Ala motifs. Understanding NAT replacement clarifies why archaeal wall inhibitors require different targets and highlights divergence of glycosyltransferase evolution. Comparative genomics indicates distinct glycosyltransferase families synthesize NAT-containing precursors, and structural studies of NAT reveal altered chair conformation due to axial carboxyl group, influencing polymer packing and crosslink spacing, properties exploited for development of lytic enzymes used for selective lysis of methanogens in anaerobic digestion studies.